129 related articles for article (PubMed ID: 34635981)
21. Functional Variant rs4442975 Modulating FOXA1 Binding Affinity Can Influence Bone Marrow Suppression during Neoadjuvant Chemotherapy for Luminal A Type Breast Cancer.
Wang X; Feng Z; Li J; Han Y; Su L; Wang F; Yang Y; Zhang Y
Biomed Res Int; 2019; 2019():7073498. PubMed ID: 30881995
[TBL] [Abstract][Full Text] [Related]
22. Androgen receptor and FOXA1 coexpression define a "luminal-AR" subtype of feline mammary carcinomas, spontaneous models of breast cancer.
Dagher E; Royer V; Buchet P; Abadie J; Loussouarn D; Campone M; Nguyen F
BMC Cancer; 2019 Dec; 19(1):1267. PubMed ID: 31888566
[TBL] [Abstract][Full Text] [Related]
23. FOXA1: a transcription factor with parallel functions in development and cancer.
Bernardo GM; Keri RA
Biosci Rep; 2012 Apr; 32(2):113-30. PubMed ID: 22115363
[TBL] [Abstract][Full Text] [Related]
24. Cancer-specific mutation of GATA3 disrupts the transcriptional regulatory network governed by Estrogen Receptor alpha, FOXA1 and GATA3.
Takaku M; Grimm SA; De Kumar B; Bennett BD; Wade PA
Nucleic Acids Res; 2020 May; 48(9):4756-4768. PubMed ID: 32232341
[TBL] [Abstract][Full Text] [Related]
25. FOXA1 antagonizes EZH2-mediated CDKN2A repression in carcinogenesis.
Zhang Y; Tong T
Biochem Biophys Res Commun; 2014 Oct; 453(1):172-8. PubMed ID: 25264199
[TBL] [Abstract][Full Text] [Related]
26. Breast cancer risk-associated SNPs modulate the affinity of chromatin for FOXA1 and alter gene expression.
Cowper-Sal lari R; Zhang X; Wright JB; Bailey SD; Cole MD; Eeckhoute J; Moore JH; Lupien M
Nat Genet; 2012 Nov; 44(11):1191-8. PubMed ID: 23001124
[TBL] [Abstract][Full Text] [Related]
27. Bisphenol A stimulates the epithelial mesenchymal transition of estrogen negative breast cancer cells via FOXA1 signals.
Zhang XL; Wang HS; Liu N; Ge LC
Arch Biochem Biophys; 2015 Nov; 585():10-16. PubMed ID: 26363213
[TBL] [Abstract][Full Text] [Related]
28. miR-204 regulates the biological behavior of breast cancer MCF-7 cells by directly targeting FOXA1.
Shen SQ; Huang LS; Xiao XL; Zhu XF; Xiong DD; Cao XM; Wei KL; Chen G; Feng ZB
Oncol Rep; 2017 Jul; 38(1):368-376. PubMed ID: 28534958
[TBL] [Abstract][Full Text] [Related]
29. Twist1 promotes breast cancer invasion and metastasis by silencing Foxa1 expression.
Xu Y; Qin L; Sun T; Wu H; He T; Yang Z; Mo Q; Liao L; Xu J
Oncogene; 2017 Feb; 36(8):1157-1166. PubMed ID: 27524420
[TBL] [Abstract][Full Text] [Related]
30. Impact of OGT deregulation on EZH2 target genes FOXA1 and FOXC1 expression in breast cancer cells.
Forma E; Jóźwiak P; Ciesielski P; Zaczek A; Starska K; Bryś M; Krześlak A
PLoS One; 2018; 13(6):e0198351. PubMed ID: 29864144
[TBL] [Abstract][Full Text] [Related]
31. Integrative functional genomics identifies an enhancer looping to the SOX9 gene disrupted by the 17q24.3 prostate cancer risk locus.
Zhang X; Cowper-Sal lari R; Bailey SD; Moore JH; Lupien M
Genome Res; 2012 Aug; 22(8):1437-46. PubMed ID: 22665440
[TBL] [Abstract][Full Text] [Related]
32. High Throughput Chemical Screening Reveals Multiple Regulatory Proteins on FOXA1 in Breast Cancer Cell Lines.
Wang S; Singh SK; Katika MR; Lopez-Aviles S; Hurtado A
Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30572598
[TBL] [Abstract][Full Text] [Related]
33. FOXA1 in breast cancer.
Nakshatri H; Badve S
Expert Rev Mol Med; 2009 Mar; 11():e8. PubMed ID: 19261198
[TBL] [Abstract][Full Text] [Related]
34. Up-regulation of the HSP72 by Foxa1 in MCF-7 human breast cancer cell line.
Song L; Xu Z; Zhang C; Qiao X; Huang C
Biochem Biophys Res Commun; 2009 Aug; 386(1):30-4. PubMed ID: 19486887
[TBL] [Abstract][Full Text] [Related]
35. Clinically-observed FOXA1 mutations upregulate SEMA3C through transcriptional derepression in prostate cancer.
Tam KJ; Liu L; Hsing M; Dalal K; Thaper D; McConeghy B; Yenki P; Bhasin S; Peacock JW; Wang Y; Cherkasov A; Rennie PS; Gleave ME; Ong CJ
Sci Rep; 2024 Mar; 14(1):7082. PubMed ID: 38528115
[TBL] [Abstract][Full Text] [Related]
36. FoxA1 as a lineage-specific oncogene in luminal type breast cancer.
Yamaguchi N; Ito E; Azuma S; Honma R; Yanagisawa Y; Nishikawa A; Kawamura M; Imai J; Tatsuta K; Inoue J; Semba K; Watanabe S
Biochem Biophys Res Commun; 2008 Jan; 365(4):711-7. PubMed ID: 18039470
[TBL] [Abstract][Full Text] [Related]
37. Delineation of a FOXA1/ERα/AGR2 regulatory loop that is dysregulated in endocrine therapy-resistant breast cancer.
Wright TM; Wardell SE; Jasper JS; Stice JP; Safi R; Nelson ER; McDonnell DP
Mol Cancer Res; 2014 Dec; 12(12):1829-39. PubMed ID: 25100862
[TBL] [Abstract][Full Text] [Related]
38. FOXA1 repression is associated with loss of BRCA1 and increased promoter methylation and chromatin silencing in breast cancer.
Gong C; Fujino K; Monteiro LJ; Gomes AR; Drost R; Davidson-Smith H; Takeda S; Khoo US; Jonkers J; Sproul D; Lam EW
Oncogene; 2015 Sep; 34(39):5012-24. PubMed ID: 25531315
[TBL] [Abstract][Full Text] [Related]
39. Functional Analysis of Promoter Variants in Genes Involved in Sex Steroid Action, DNA Repair and Cell Cycle Control.
Hamdi Y; Leclerc M; Dumont M; Dubois S; Tranchant M; Reimnitz G; Soucy P; Cassart P; Ouimet M; Sinnett D; Chaieb MLL; Simard J
Genes (Basel); 2019 Feb; 10(3):. PubMed ID: 30823486
[TBL] [Abstract][Full Text] [Related]
40. Unbiased analysis of potential targets of breast cancer susceptibility loci by Capture Hi-C.
Dryden NH; Broome LR; Dudbridge F; Johnson N; Orr N; Schoenfelder S; Nagano T; Andrews S; Wingett S; Kozarewa I; Assiotis I; Fenwick K; Maguire SL; Campbell J; Natrajan R; Lambros M; Perrakis E; Ashworth A; Fraser P; Fletcher O
Genome Res; 2014 Nov; 24(11):1854-68. PubMed ID: 25122612
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
